Search Clinical Trials in the EU

Duration

Visits

Confirmation phase (III)

Intake methods

Benefits

Drugs

Locations

Clinical Specialty

721-740 of 1,307 trials

Multiple Myeloma: Anitocabtagene Autoleucel Study

We are comparing a new treatment called anitocabtagene autoleucel with standard therapies for patients with relapsed or refractory multiple myeloma. The goal is to see which option works better and is safer for patients.

Relapsed/Refractory Multiple MyelomaConfirmation phase (III)No Placebo Investigational Medicines Cost Reimbursement Partially RemoteHematologyOncology

Hereditary Transthyretin-Mediated Amyloid Polyneuropathy: ION-682884 Study

We are assessing the long-term safety and effectiveness of ION-682884 in patients with hereditary transthyretin-mediated amyloid polyneuropathy. This study aims to understand how well the treatment works over time.

Familial Amyloid PolyneuropathyConfirmation phase (III)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteInternal MedicineNeurology

Epithelial Ovarian Cancer: Letrozole Maintenance Therapy

We are studying whether letrozole can help women with epithelial ovarian cancer stay cancer-free after surgery and chemotherapy. This trial compares letrozole to a placebo to see if it improves outcomes.

Ovarian Epithelial CancerConfirmation phase (III)11-15 visits Investigational MedicinesGynecology and ObstetricsOncology

Non-Small Cell Lung Cancer: Alectinib and Chemotherapy Study

We are investigating how well alectinib combined with chemotherapy works for patients with early-stage non-small cell lung cancer. This study focuses on those whose cancer can be surgically removed and who have specific biomarker characteristics.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)No Placebo Standard Medicines Cost Reimbursement Partially RemoteOncology

Blood Cancer: Long-term Study of Zanubrutinib

We are evaluating the long-term safety and effectiveness of Zanubrutinib in patients with B-cell malignancies. This study is for those who have previously participated in a related trial.

B-cell Lymphoma>2 yearsConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteHematologyOncology

Refractory Invasive Pulmonary Aspergillosis: Nebulized PC945

We are studying a new nebulized treatment, PC945, for patients with a tough-to-treat fungal infection. The goal is to see if it works better when combined with standard antifungal therapies.

Pulmonary Aspergillosis3-6 monthsConfirmation phase (III)11-15 visits Investigational Medicines Cost Reimbursement Partially RemoteInfectious DiseasesPulmonology

Cholestatic Pruritus: Maralixibat Study

We are testing a new medication, maralixibat, for individuals with cholestatic pruritus to see if it can reduce itching and lower bile acid levels in the blood.

Cholestatic PruritusConfirmation phase (III)Post-Trial Drug Access Standard Medicines Partially RemoteDermatologyHepatology

Advanced Non-Small Cell Lung Cancer: BAY 2927088 Study

We are investigating how well BAY 2927088 works and its safety compared to standard treatment for patients with advanced non-small cell lung cancer with HER2 mutations.

Advanced Non-Small Cell Lung Cancer with HER2 MutationConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncology

Acute Pulmonary Embolism: Reduced Dose Thrombolytic Treatment

We are studying whether a lower dose of thrombolytic therapy is effective and safe for patients with intermediate high-risk acute pulmonary embolism. This research aims to improve treatment outcomes and reduce health risks.

Pulmonary Embolism>2 yearsConfirmation phase (III)≤5 visits Investigational MedicinesCardiologyInternal MedicinePulmonology

Colchicine for Knee and Hip Osteoarthritis

We are studying whether colchicine can help reduce the need for knee or hip replacements in people with osteoarthritis. The trial also looks at its effects on pain, physical function, and overall quality of life.

Osteoarthritis>2 yearsConfirmation phase (III)6-10 visits Standard Medicines Cost Reimbursement Partially RemoteOrthopedics and TraumatologyRheumatology

Hidradenitis Suppurativa: Sonelokimab Treatment Study

We are testing a new injectable medication, sonelokimab, for adults with moderate to severe hidradenitis suppurativa. The study aims to see if it can improve symptoms compared to a placebo.

Hidradenitis Suppurativa1-2 yearsConfirmation phase (III)16-20 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementAllergologyDermatology

Atopic Dermatitis: Methylprednisolone Aceponate Cream

We are comparing a new cream for atopic dermatitis with an existing treatment and a placebo. The goal is to see if it is more effective and safe for reducing symptoms.

Mild to Moderate Atopic DermatitisConfirmation phase (III)≤5 visits Investigational MedicinesDermatology

NRAS Mutant Melanoma: Naporafenib + Trametinib Study

We are testing a new combination therapy for patients with previously treated NRAS mutant cutaneous melanoma. The goal is to see if it works better than standard treatment options in improving survival and managing the disease.

Unresectable or Metastatic NRAS Mutant Cutaneous Melanoma>2 yearsConfirmation phase (III)No Placebo Investigational MedicinesDermatologyOncology

Metastatic Breast Cancer: New HER2 Imaging Test

We are studying a new imaging method using 68Ga-ABS011 to see how well it detects HER2 status in metastatic breast cancer and other solid tumors. This may help improve diagnosis and treatment management.

Metastatic Breast Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)No Placebo Standard Medicines Cost ReimbursementInternal MedicineOncology

Rheumatoid Arthritis: Baricitinib and Anti-TNF Combination Study

We are investigating whether combining baricitinib with anti-TNF therapy helps patients with rheumatoid arthritis who haven't responded to other treatments. The study will also look at safety and how well patients can reduce their steroid use.

Rheumatoid Arthritis6-12 monthsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational MedicinesRheumatology

Ulcerative Colitis: Filgotinib for Kids and Teens

We are studying the effects of filgotinib in children and teenagers with moderately to severely active ulcerative colitis. The trial aims to see if it helps achieve remission and improves quality of life.

Ulcerative Colitis1-2 yearsConfirmation phase (III)6-10 visits No Placebo Investigational Medicines Cost Reimbursement Partially RemoteGastroenterologyPediatrics

Crohn's Disease in Children: Mirikizumab Study

We are studying whether Mirikizumab can help children with moderately to severely active Crohn's Disease achieve better health compared to a placebo. This research aims to improve treatment options for young patients.

Crohn's Disease1-2 yearsConfirmation phase (III)16-20 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementGastroenterologyPediatrics

Chronic Myeloid Leukemia: Olverembatinib Study

We are testing a new drug, Olverembatinib, for patients with Chronic Phase Chronic Myeloid Leukemia. The study aims to see if it works better than the current treatment, Bosutinib, especially for those with a specific mutation.

Chronic Myeloid Leukemia1-2 yearsConfirmation phase (III)Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteHematologyOncology

RECLAIM: Treatments for Long COVID

We are studying different treatments for people suffering from long COVID to see how they improve physical and mental health. The trial will also assess specific symptoms like fatigue and cognitive difficulties.

Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)3-6 monthsConfirmation phase (III)6-10 visits Standard Medicines Partially RemoteInfectious DiseasesInternal Medicine

Locally-Advanced Rectal Cancer: Tailored Treatment Study

We are studying a personalized treatment plan for patients with locally-advanced rectal cancer who respond well to initial chemotherapy. The goal is to see if this approach maintains effective surgery outcomes while reducing treatment intensity.

Rectal Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)No Placebo Standard MedicinesOncology

Search Clinical Trials in the European Union